CADLCandel Therapeutics, Inc.Running, no new patients
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Prostate Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Nov 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 187 (final count)
- Started
- May 2016
- Main results expected
- Nov 2024
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Baseline to study completion, approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-11-01, no fading
Raw record changes
- none yet
Trial ID NCT02768363 · record last updated 2026-10-02 · checked 2026-11-09 15:47 UTC